nanoprobes

Nanoprobes are nanoscale constructs designed to detect, visualize, or influence biological processes by interacting with specific molecular targets. They translate molecular events into measurable signals—such as photons, magnetic signals, or electrochemical outputs—allowing researchers to observe cellular activities in real time or to diagnose diseases with high sensitivity. Nanoprobes span inorganic, organic, and hybrid materials and are used mainly in imaging, biosensing, and therapeutic monitoring; some are developed as theranostic agents that combine diagnosis and therapy.

Common nanoprobe platforms include quantum dots (semiconductor nanoparticles with size-tunable fluorescence), gold nanoparticles used for plasmonic sensing and as SERS substrates, iron oxide nanoparticles for magnetic resonance imaging, and upconversion or carbon-based nanomaterials. They can generate signals across modalities including fluorescence, MRI, CT, photoacoustic imaging, and electrochemical readouts. The signal generation depends on the material: luminescence from emitters, magnetic relaxation for MRI, or enhanced scattering for SERS.

To achieve specificity, nanoprobes are functionalized with targeting ligands such as antibodies, aptamers, peptides, or small molecules, and often coated with polymers (for example PEG) to improve biocompatibility and pharmacokinetics. Multimodal or multiplexed nanoprobes enable simultaneous detection of multiple targets or integration of imaging modalities in a single agent.

Applications include cancer imaging and detection, monitoring of drug delivery and treatment response, infectious disease diagnostics, and neuroscience research. In clinical use, iron oxide–based nanoprobes are established MRI contrast agents in some markets, while many other nanoprobe systems remain under investigation in preclinical studies or clinical trials. Safety concerns focus on toxicity from heavy metals, long-term biodistribution and clearance, and reproducibility of synthesis and functionalization. Ongoing development aims to improve biocompatibility, targeting efficiency, and regulatory approval timelines.